Filing Flows › Comparisons › MIRM vs PCRX
Mirum Pharmaceuticals vs Pacira BioSciences: MIRM and PCRX compared
Mirum Pharmaceuticals is the larger company: $186M of revenue in its latest quarter (Q3 2026) against $177M for Pacira BioSciences (Q3 2026). Mirum Pharmaceuticals is growing faster (+40% against -2% a year earlier). Pacira BioSciences is more profitable, with an operating margin of 12.6% against -32.2%.
Where the money goes: MIRM and PCRX
Mirum Pharmaceuticals (MIRM) · Q3 2026
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
Pacira BioSciences (PCRX) · Q3 2026
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
| Mirum Pharmaceuticals (MIRM) | Pacira BioSciences (PCRX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $186M | $177M |
| Revenue growth, Y/Y | +40% | -2% |
| Operating margin | -32.2% | 12.6% |
| Net earnings | −$40.8M | $28.5M |
| Net margin | -22.0% | 16.1% |
| Operating cash flow | −$4.3M | $50.1M |
| Free cash flow | — | $46.4M |
| Market value | — | $1.5B |
| P/E | — | 100.3× |
| Analysts’ mean target | — | $33.57 |
Where the revenue comes from
Mirum Pharmaceuticals
- Livmarli: $133M (72%)
- Bile Acid Medicines: $52.3M (28%)
Pacira BioSciences
- Net product sales: $175M (99%)
- Bupivacaine liposome injectable suspension: $1.2M (1%)
Questions
Which is bigger, Mirum Pharmaceuticals or Pacira BioSciences?
Mirum Pharmaceuticals is the larger company: $186M of revenue in its latest quarter (Q3 2026) against $177M for Pacira BioSciences (Q3 2026).
Is Mirum Pharmaceuticals or Pacira BioSciences growing faster?
Mirum Pharmaceuticals is growing faster (+40% against -2% a year earlier).
Which is more profitable, Mirum Pharmaceuticals or Pacira BioSciences?
Pacira BioSciences is more profitable, with an operating margin of 12.6% against -32.2%.
More: Mirum Pharmaceuticals earnings · how Mirum Pharmaceuticals makes money · Pacira BioSciences earnings · how Pacira BioSciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.